<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> associated macrophages (TAMs) are considered with the capacity to have both negative and positive effects on <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The prognostic value of TAM for survival in patients with <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> remains controversial </plain></SENT>
<SENT sid="2" pm="."><plain>EXPERIMENTAL DESIGN: We conducted a meta-analysis of 55 studies (n = 8,692 patients) that evaluated the correlation between TAM (detected by immunohistochemistry) and clinical staging, overall survival (OS) and disease free survival (DFS) </plain></SENT>
<SENT sid="3" pm="."><plain>The impact of M1 and M2 type TAM (n = 5) on survival was also examined </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: High density of TAM was significantly associated with late clinical staging in patients with <z:hpo ids='HP_0003002'>breast cancer</z:hpo> [risk ratio (RR)  = 1.20 (95% confidence interval (CI), 1.14-1.28)] and <z:e sem="disease" ids="C0005684" disease_type="Neoplastic Process" abbrv="">bladder cancer</z:e> [RR = 3.30 (95%CI, 1.56-6.96)] and with early clinical staging in patients with <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> [RR = 0.52 (95%CI, 0.35-0.77)] </plain></SENT>
<SENT sid="5" pm="."><plain>Negative effects of TAM on OS was shown in patients with <z:hpo ids='HP_0012126'>gastric cancer</z:hpo> [RR = 1.64 (95%CI, 1.24-2.16)], <z:hpo ids='HP_0003002'>breast cancer</z:hpo> [RR = 8.62 (95%CI, 3.10-23.95)], <z:e sem="disease" ids="C0005684" disease_type="Neoplastic Process" abbrv="">bladder cancer</z:e> [RR = 5.00 (95%CI, 1.98-12.63)], <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> [RR = 2.55 (95%CI, 1.60-4.06)], <z:e sem="disease" ids="C0153381" disease_type="Neoplastic Process" abbrv="">oral cancer</z:e> [RR = 2.03 (95%CI, 1.47-2.80)] and <z:e sem="disease" ids="C0007115" disease_type="Neoplastic Process" abbrv="">thyroid cancer</z:e> [RR = 2.72 (95%CI, 1.26-5.86)],and positive effects was displayed in patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> [RR = 0.64 (95%CI, 0.43-0.96)] </plain></SENT>
<SENT sid="6" pm="."><plain>No significant effect was showed between TAM and DFS </plain></SENT>
<SENT sid="7" pm="."><plain>There was also no significant effect of two phenotypes of TAM on survival </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Although some modest bias cannot be excluded, high density of TAM seems to be associated with worse OS in patients with <z:hpo ids='HP_0012126'>gastric cancer</z:hpo>, <z:e sem="disease" ids="C0751569" disease_type="Neoplastic Process" abbrv="">urogenital cancer</z:e> and <z:e sem="disease" ids="C0278996" disease_type="Neoplastic Process" abbrv="">head and neck cancer</z:e>, with better OS in patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>